Litcius/Paper detail

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han, Yufei Song, Changgui Li, Wanqi Yang, Qingxia Ma, Zhiwei Jiang, Minjie Li, Xiaojuan Lian, Wenbin Jiao, Lei Wang, Qun Shu, Zhiwei Wu, Yuliang Zhao, Qi Li, Qiang Gao

2021The Lancet Infectious Diseases355 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTolerabilityClinical endpointSeroconversionPopulationAdverse effectClinical trialImmunogenicityRandomized controlled trialAdjuvantInternal medicinePediatricsImmunologyAntibodyEnvironmental healthSARS-CoV-2 and COVID-19 ResearchIntramuscular injections and effectsVirology and Viral Diseases
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial | Litcius